Shenzhen-based SainuoSheng Gene Industry Development Co. is preparing for a Hong Kong main board listing, leveraging two decades of experience with the world’s first approved gene therapy drug, Gendicine.
Gendicine, a recombinant human p53 adenovirus injection, was approved in China in 2003 and has treated over 100,000 patients. The therapy underpins SainuoSheng’s large-scale GMP production capabilities and its virus-vector gene therapy CDMO platform, designed to address industry challenges in cost and mass manufacturing.
The company aims to attract strategic investors as it positions its dual model of steady revenue from Gendicine and high-value CDMO services for a potential IPO in the second half of 2026.
